RMD · Resmed Inc · Financials
$245.50
+5.73 (+2.39%)
At close · Oct 20
Return incl. dividend (before tax)
Market Cap
$34.59B
Shares
144.25M
Volume · Oct 20
1.24M
Avg daily vol (3M)
1.31M
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$5.65B
+9.9%
FY2026
Net Income
$1.52B
+8.8%
FY2026
Gross Margin
61.06%
+1.7pp
FY2026
Operating Margin
33.37%
+0.6pp
FY2026
Diluted EPS
$10.43
+9.7%
FY2026
Operating Cash Flow
$1.81B
+3.1%
FY2026
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| — | $5.65B | $5.15B | $4.69B | $4.22B | $3.58B | $3.2B | $2.96B | $2.61B | $2.34B | $2.07B | $1.84B | $1.68B | $1.55B | $1.51B | $1.37B | $1.24B | $1.09B | $920.74M | |
| -$54.73M | — | — | — | -$47.38M | -$22.31M | -$23.63M | -$39.36M | — | — | — | — | — | — | — | — | — | — | — | |
| — | — | — | — | — | $90.08M | $93.43M | $87.87M | — | — | — | — | — | — | — | — | — | — | — | |
| — | $2.2B | $2.09B | $2.03B | $1.87B | $1.55B | $1.36B | $1.24B | $1.11B | $1.01B | $864.99M | $772.22M | $667.52M | $565.19M | $573.8M | $547.78M | $501.82M | $436.87M | $366.93M | |
| — | $3.45B | $3.05B | $2.66B | $2.36B | $2.02B | $1.84B | $1.72B | $1.49B | $1.33B | $1.2B | $1.07B | $1.01B | $989.79M | $940.66M | $820.74M | $741.33M | $655.48M | $553.8M | |
| — | 61.06% | 59.36% | 56.67% | 55.78% | 56.57% | 57.53% | 58.09% | 57.32% | 57.04% | 58.15% | 58% | 60.24% | 63.65% | 62.11% | 59.97% | 59.63% | 60.01% | 60.15% | |
| — | $378.29M | $331.28M | $307.53M | $287.64M | $253.58M | $225.28M | $201.95M | $180.65M | $155.15M | $144.47M | $118.65M | $114.87M | $118.23M | $120.12M | $109.73M | $92.01M | $75.2M | $63.06M | |
| — | $1.12B | $993.05M | $917.14M | $874M | $737.51M | $670.39M | $676.69M | $645.01M | $600.37M | $553.97M | $488.06M | $478.63M | $450.41M | $430.8M | $402.62M | $372.25M | $328.86M | $289.88M | |
| — | $31.78M | $32.12M | $32.96M | $30.4M | $39.65M | $45.13M | $49.6M | $42.51M | $27.27M | $46.6M | $30.2M | $15M | $15.9M | $17M | $13.97M | $10.15M | $8.04M | $7.06M | |
| — | $201.34M | $198.47M | $176.87M | $165.16M | $159.61M | $156.76M | $154.85M | $150.8M | $119.96M | $112.16M | $86.85M | $73.06M | $73.45M | $78.28M | $85.86M | $70.62M | $61.56M | $53.96M | |
| — | $21.75M | $0 | $64.23M | $9.18M | $0 | $8.67M | $0 | $9.4M | $18.43M | $12.36M | $6.91M | — | $6.33M | — | — | — | — | — | |
| — | $1.57B | $1.37B | $1.34B | $1.22B | $1.02B | $935.42M | $908.13M | $914.81M | $793.07M | $775.95M | $637.55M | $602.16M | $584.7M | $585.83M | $526.33M | $474.4M | $415.1M | $363.49M | |
| — | $1.89B | $1.69B | $1.32B | $1.13B | $1B | $903.68M | $809.66M | $579.26M | $541.83M | $425.8M | $428.95M | $409.24M | $405.09M | $354.82M | $294.41M | $266.92M | $240.38M | $190.31M | |
| — | 33.37% | 32.75% | 28.17% | 26.8% | 27.96% | 28.27% | 27.38% | 22.22% | 23.15% | 20.6% | 23.33% | 24.38% | 26.05% | 23.43% | 21.51% | 21.47% | 22.01% | 20.67% | |
| — | $2.09B | $1.88B | $1.5B | $1.3B | $1.16B | $1.06B | $964.51M | $730.06M | $661.79M | $537.96M | $515.8M | $482.29M | $478.54M | $433.1M | $380.26M | $337.54M | $301.95M | $244.27M | |
| $22.42M | — | — | — | — | — | $23.99M | $40.38M | $36.16M | $28.36M | $28.24M | $11.21M | $5.78M | $6.13M | $6.39M | $4.79M | $1.76M | $2.67M | — | |
| — | — | — | — | — | — | $362K | $1.02M | $2.3M | $16.38M | $17.09M | $16.86M | $26.21M | $31.24M | $38.87M | $33.87M | $27.8M | $16.7M | $10.21M | |
| — | $32.7M | -$7.8M | -$55.1M | -$30.21M | -$39.8M | -$20.02M | -$76.57M | -$60.42M | -$20.52M | -$7.06M | $10.61M | $26.68M | $25.99M | $30.3M | $37.54M | $36.78M | $20.21M | $11.37M | |
| — | $6.96M | $3.64M | -$1.85M | -$7.27M | -$8.49M | -$11.21M | -$25.06M | -$15.83M | — | — | — | — | — | — | — | — | — | — | |
| — | $1.92B | $1.68B | $1.26B | $1.1B | $960.48M | $883.66M | $733.09M | $518.85M | $521.31M | $418.74M | $439.57M | $435.92M | $431.08M | $385.12M | $331.95M | $303.71M | $260.59M | $201.68M | |
| — | $396.12M | $276.84M | $243.85M | $204.11M | $181.05M | $409.16M | $111.41M | $114.26M | $205.72M | $76.46M | $87.16M | $83.03M | $85.81M | $77.99M | $77.1M | $76.72M | $70.5M | $55.24M | |
| — | $1.52B | $1.4B | $1.02B | $897.56M | $779.44M | $474.51M | $621.67M | $404.59M | $315.59M | $342.28M | $352.41M | $352.89M | $345.27M | $307.13M | $254.85M | $226.99M | $190.09M | $146.45M | |
| — | 26.94% | 27.22% | 21.79% | 21.25% | 21.78% | 14.84% | 21.02% | 15.52% | 13.49% | 16.56% | 19.17% | 21.02% | 22.2% | 20.28% | 18.62% | 18.26% | 17.4% | 15.91% | |
| — | $1.52B | $1.58B | $1.04B | $937.78M | $660.18M | $565M | $590.7M | $375.91M | $280.32M | $375.88M | $303.27M | $27.81M | $404.74M | $162.77M | $166.87M | $465.04M | $86.38M | — | |
| USD/shares | — | $10.47 | $9.55 | $6.94 | $6.12 | $5.34 | $3.27 | $4.31 | $2.83 | $2.21 | $2.42 | $2.51 | $2.51 | $2.44 | $2.15 | $1.75 | $1.49 | $1.26 | $0.97 |
| USD/shares | — | $10.43 | $9.51 | $6.92 | $6.09 | $5.30 | $3.24 | $4.27 | $2.80 | $2.19 | $2.40 | $2.49 | $2.47 | $2.39 | $2.10 | $1.71 | $1.44 | $1.23 | $0.95 |
| shares | — | 145.52M | 146.72M | 147.02M | 146.77M | 146.07M | 145.31M | 144.34M | 143.11M | 142.76M | 141.36M | 140.24M | 140.47M | 141.47M | 142.95M | 145.9M | 152.47M | 150.91M | 151.26M |
| shares | — | 146.05M | 147.34M | 147.55M | 147.46M | 147.04M | 146.45M | 145.65M | 144.48M | 143.99M | 142.45M | 141.67M | 142.69M | 144.36M | 146.41M | 149.32M | 157.2M | 155.1M | 154.23M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2009–FY2026: $2.63B in buybacks, $3.06B in dividends.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Latest reported total
USD 660,000,000
As of Jun 30, 2026
Tracked instruments
0
Loans, facilities and note series
Annual baseline
Jun 30, 2026
Latest approved annual total
Reported total debt history
| As of | Reported label | Amount | Source |
|---|---|---|---|
| 2026-06-30 | total outstanding debt | USD 660,000,000 |
10-K filed 2026-08-13
Our leverage and debt service obligations could adversely affect our business. As of June 30, 2026, our total outstanding debt was $660 million and we may incur additional indebtedness in the future. Our indebtedness could have adverse consequences, including: |
| 2025-06-30 | total consolidated debt | USD 700,000,000 |
10-K filed 2025-08-08
Our leverage and debt service obligations could adversely affect our business. As of June 30, 2025, our total consolidated debt was $0.7 billion and we may incur additional indebtedness in the future. |
| 2024-06-30 | total consolidated debt | USD 700,000,000 |
10-K filed 2024-08-09
Our leverage and debt service obligations could adversely affect our business. As of June 30, 2024, our total consolidated debt was $0.7 billion and we may incur additional indebtedness in the future. |
| 2023-06-30 | total consolidated debt | USD 1,400,000,000 |
10-K filed 2023-08-11
Our leverage and debt service obligations could adversely affect our business. As of June 30, 2023, our total consolidated debt was $1.4 billion and we may incur additional indebtedness in the future. |
| 2022-06-30 | our total consolidated debt | USD 800,000,000 |
10-K filed 2022-08-12
Our leverage and debt service obligations could adversely affect our business. As of June 30, 2022, our total consolidated debt was $0.8 billion and we may incur additional indebtedness in the future, including as a result of our pending acquisition of MEDIFOX DAN, which is expected to close during our fiscal year 2023. |
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Long-term debt, including current maturities | 2026-06-30 | USD 399,415,000 | 10-K filed 2026-08-13 |
| Operating lease liabilities | 2026-06-30 | USD 166,554,000 | 10-K filed 2026-08-13 |
Related accounting measures — not additional borrowingCarrying amounts can reflect issuance costs or discounts. Differences between these measures are not necessarily repayments due within a year.
| |||
| Short-term borrowings | 2026-06-30 | USD 259,950,000 | 10-K filed 2026-08-13 |
9 filing observations remain unmatched and are excluded from instrument histories.
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
10 filings have incomplete source or extraction coverage. Verified observations are shown; missing observations do not establish that debt was unchanged.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
5.97×
Peer median 2.30×
EV/EBIT
17.90×
Peer median 29.72×
P/E (TTM)
22.99×
Peer median 37.02×
Peer medians compare against the 17 similar-size Medical Instruments & Supplies companies (of 51 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $4,977,630,000 | $4,504,890,000 | $4,101,172,000 | $3,725,017,000 | $3,177,298,000 | $2,823,235,000 | $2,602,381,000 | $2,330,783,000 |
| Residential Care Software | $675,813,000 | $641,437,000 | $584,125,000 | $497,976,000 | $400,829,000 | $373,590,000 | $354,632,000 | $275,789,000 |
| Software as Service Before Deferred Revenue Adjustment | — | — | — | — | — | — | — | $281,137,000 |
By Geography (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| United States | $3,562,024,000 | $3,285,581,000 | $2,980,053,000 | $2,719,923,000 | $2,249,381,000 | $1,962,721,000 | $1,828,575,000 | $1,588,655,000 |
| Non Us | $2,091,419,000 | $1,860,746,000 | $1,705,244,000 | $1,503,070,000 | $1,328,746,000 | $1,234,104,000 | $1,128,438,000 | $1,017,917,000 |
| U.S. Canada and Latin America | — | — | — | — | $2,382,636,000 | $2,078,703,000 | $1,926,959,000 | $1,696,285,000 |
By Product & Service (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $4,977,630,000 | $4,504,890,000 | $4,101,172,000 | $3,725,017,000 | $3,177,298,000 | $2,823,235,000 | $2,602,381,000 | $2,330,783,000 |
| Residential Care Software | $675,813,000 | $641,437,000 | $584,125,000 | $497,976,000 | $400,829,000 | $373,590,000 | $354,632,000 | $275,789,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Sleep and Breathing Health | $2,204,498,000 | $1,964,385,000 | $1,681,354,000 | $1,447,120,000 | $1,279,591,000 | — | — | — |
| Residential Care Software | $217,731,000 | $205,000,000 | $154,450,000 | $115,655,000 | $93,756,000 | $92,357,000 | — | — |
| Devices and Masks | — | — | — | $1,502,475,000 | $1,311,559,000 | $1,170,305,000 | $934,697,000 | $766,068,000 |
| Software as Service | — | — | — | — | $93,821,000 | $93,037,000 | $82,152,000 | $74,886,000 |
Operating Margin by Segment (%)
| Component | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Sleep and Breathing Health | 44.3% | 43.6% | 41% | 38.8% | 40.3% | — |
| Residential Care Software | 32.2% | 32% | 26.4% | 23.2% | 23.4% | 24.7% |
Key facts
CIK
943819
CUSIP
761152107
13F (30d)
125 filings
120 filers
Visit website
Investor relations